You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
「減肥神藥」丹麥Novo Nordisk力壓軟件巨擘SAP 重奪歐洲最高市值上市公司地位
阿思達克 06-13 17:24
生產「減肥神藥」的丹麥諾和諾德(Novo Nordisk)週五(13日)曾升2.3%,市值高達3,650億美元,力壓軟件巨擘SAP(市值約3,643億美元),重拾歐洲最高市值上市公司地位。 集團表示,收到監管機構回饋,計劃推進實驗減肥藥amycretin的後期階段發展。 諾和諾德自去年6月股價創歷史高位後,面對一連串挫折,包括實驗性減肥藥臨牀數據欠佳,以及來自美國同業禮來(LLY.US)的競爭壓力加劇。諾和諾德上月決定撤換CEO Lars Fruergaard Jorgensen。 集團本週股價上升,有外電報道指,維權基金Parvus Asset Management對其建倉,希望左右諾和諾德新CEO的任命。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account